CClinicalTrials.gg
Sign In
Not yet recruitingNCT06760650Fluo-AKIUpdated Jan 7, 2025

Fluorescein Angiography in Patients With Diabetes and Chronic Kidney Disease

An interventional study of Fluorescein angiography in Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 3B and Chronic Kidney Disease Stage 5, sponsored by Saint-Joseph University. Not yet recruiting at 1 site in Lebanon. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-07.

Sponsored by Saint-Joseph University · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Oct 2025, 11 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Our study hypothesizes that fluorescein exposure in diabetic patients with advanced chronic kidney disease results in deterioration of kidney function. It will therefore aim to evaluate the incidence of acute kidney injury induced by fluorescein in diabetic patients with CKD. The objective is to determine the incidence, severity and risk factors associated with this deterioration to improve the care of this specific population.

Read the detailed description

This study will assess the change in serum creatinine in patients with diabetes and advanced chronic kidney disease, after a fluorescein angiography. This is a before and after study that will include 35 patients from the department of ophtalmology over 6 months with a total follow-up for 3 months.

02

Conditions studied

  • Chronic Kidney Disease Stage 4
  • Chronic Kidney Disease Stage 3B
  • Chronic Kidney Disease Stage 5
  • Diabetes Mellitus
  • Fluorescein Angiography
  • Acute Kidney Injury

Keywords

  • Fluorescein Angiography
  • Acute kidney injury
  • Chronic kidney disease
  • Diabetes
03

In context

Kidney Diseases

3,840 studies on the registry are indexed under Kidney Diseases; 500 are open to participants now.

This study's planned enrollment of 35 is below the median of 70 across 2,640 interventional studies indexed under Kidney Diseases.

Browse Kidney Diseases studies →

Lead sponsor

Saint-Joseph University is the lead sponsor of 71 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • >18 years old with type 2 or type 1 diabetes and chronic kidney disease stage 3b to 5 (eGFR\<45 mL/min/1.73 m2)

Exclusion criteria

Exclusion Criteria:

  • Patients who do not give their consent
  • Patients who are allergic to fluorescein
  • Patients who are on dialysis
  • Patients who had fever, vomiting, diarrhea or any dehydration 48 hours before the intervention
  • Patients who had a treatment modification one week before the intervention
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Fluorescein angiography

    Assessing serum creatinine before and after fluorescein angiography

    Diagnostic Test: Fluorescein angiography

Interventions

  • Diagnostic testFluorescein angiography

    Fluorescein angiography

    Also known as: Fluorescein fundus angiography

06

What researchers measure

Primary outcomes

  1. Change in serum creatinine

    Change in serum creatinine from baseline to day 4

    Time frame: At day 4

Secondary outcomes

  1. Long-term change in serum creatinine

    Change in serum creatinine from baseline to end of the third month

    Time frame: 3 months

07

Study locations

1 site
  • Faculty of Medicine, Saint Joseph University of Beirut
    Beirut, 56100, Lebanon
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06760650
Lead sponsor
Saint-Joseph University
Responsible party
Mabel Aoun (Associate Professor, Saint-Joseph University) — Principal investigator
First posted
Jan 7, 2025
Start date
Jan 7, 2025 (estimated)
Primary completion
Oct 10, 2025 (estimated)
Completion
Oct 10, 2025 (estimated)
Last update
Jan 7, 2025

Study contacts

Mabel AOUN, M.D., M.P.H.
Contact
aounmabel@yahoo.fr
+9613351588
Anthony NOHRA, Medical Student
Contact
anthony.nohra1@net.usj.edu.lb
Mabel AOUN, M.D., M.P.H.
principal investigator · Faculty of Medicine, Saint Joseph University of Beirut

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Kidney Diseases→

Other studies from this sponsor

Saint-Joseph University

Start the discussion